Antiglucocorticoid Augmentation of antiDepressants in Depression

Depression Clinical Trial

— ADD  

Official title:

Antiglucocorticoid Augmentation of antiDepressants in Depression

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01375920
• Other study ID #: EME-08/43/39
• Secondary ID: ISRCTN2009-01516
• Status: Completed
• Phase: Phase 3
• First received: June 17, 2011
• Last updated: July 16, 2014
• Start date: February 2011
• Est. completion date: June 2013

Study information

• Verified date: July 2014
• Source: Northumberland, Tyne and Wear NHS Foundation Trust
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Research Ethics CommitteeUnited Kingdom: Medicines and Healthcare Products Regulatory Agency
• Study type: Interventional

Clinical Trial Summary

Depression is one of the most common mental health problems, with at least one in six adults suffering from this at some time in their life. It can become long-lasting and frequently recurs. Depression has a large negative impact on quality of life of patients and their carers and it has also been shown to be one of the leading causes of working age adults receiving disability payments in the UK. The need for improved treatment has been recognised by the Department of Health and others. Improvements in drug treatments are therefore required. There has been recent increased understanding of some of the causes of the frequent lack of complete response seen with antidepressants. The stress hormone, cortisol, is often elevated or poorly controlled in depression and there is laboratory and clinical research to show that this hormonal change reduces the benefits from antidepressants with associated poor outcome and memory problems. Recently it has been shown in small studies that giving treatments that reduce cortisol or block its harmful effects for between 1 and 3 weeks overcome these negative consequences. Our group is particularly interested and experienced in this topic. The investigators plan to study a drug that decreases cortisol levels in people who have not recovered with standard antidepressants so that the investigators can find out the usefulness of this treatment (compared with placebo (dummy tablet)) in day to day life as well as checking closely for side-effects (the initial studies have shown that the particular drug the investigators wish to study (metyrapone) has few side effects). The investigators will also measure cortisol and see if its level can tell us which people do best with this treatment. The investigators will carry out this study in 3 centres across the UK. The investigators will carry out some additional tests of specific sorts of memory and decision making and also do this while scanning the brain (in a painless test). The results of these tests, along with tests of brain wave patterns, should help us understand more fully how this new treatment is working and who responds best to it. The study will help us find out if this drug should be used more widely for people not responding to standard treatments and will also lead on to the development of other new treatments with an anti-cortisol effect to help tackle the major problem of poor outcome from depression.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 190
• Est. completion date: June 2013
• Est. primary completion date: February 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Patient Inclusion Criteria:

1. Depression Severity: Hamilton Depression Rating Scale (HDRS17) score =18, consistent with a moderate to severe episode. The stability of the patient's clinical state will also be assessed at week 0. A repeat HDRS17 score at time 0 is required =18 or greater.

2. Treatment refractoriness: assessed using the Massachusetts General Hospital (MGH) staging method. This defines minimum effective doses of all currently-available antidepressants and an "adequate trial" as being for at least six weeks. For the trial to be considered a "failure", it must have been considered by the clinical team to have been ineffective rather, than the drug not having been taken or tolerated. Patients must have failed to have responded to at least their second trial of an antidepressant. This equates to a minimum score of two on MGH staging. The maximum MGH score for inclusion in the study will be 10. A UK study showed mean MGH scores in primary care patients of less than one, in secondary care mental health settings of around five and of 11 in a population of patients referred to a tertiary centre (Dr D Christmas, Dundee, Personal Communication).

3. Current antidepressant treatment: patients must be taking monotherapy or combination antidepressant therapy which includes a serotonergic drug (an SSRI, a tertiary amine tricyclic, venlafaxine, duloxetine or mirtazapine). They must not be on noradrenergic antidepressant monotherapy (e.g. with lofepramine, imipramine or reboxetine). At the point of randomisation, patients must have been on their current antidepressant medication, at the current dose, for a minimum of four weeks.

4. Age: 18-65. For the mechanistic sub-studies the patients upper age limit is 60.

Healthy Control Inclusion Criteria:

1. Aged 18-60.

2. Currently psychiatrically well, confirmed through SCID interview. HDRS17 score of =5, and no current psychotropic medication.

3. No past history of psychiatric illness, as revealed by SCID interview, or requiring any treatment (formal psychotherapy or psychotropic medication).

4. No first degree family history of psychiatric illness.

Patient Exclusion Criteria:

1. Any other DSM IV Axis I disorder other than an anxiety disorder unless the depressive episode is considered to be secondary to the anxiety disorder, confirmed using the Structured Clinical Interview for DSM (SCID).

2. Physical co-morbidity which would render the use of Metyrapone inappropriate, including untreated hypothyroidism, disorders of steroid production, current, severe cardiac failure, current, severe or frequent angina, current renal failure or myocardial infarction within the last year.

3. Pregnancy, determined by history and, if indicated, urine pregnancy test.

4. Mothers who are breastfeeding.

5. Use of concomitant medication that would interfere, in a pharmacodynamic or pharmacokinetic manner, with Metyrapone.

6. Dependence on alcohol or other drug in the past 12 months, and/or current harmful use of alcohol or other drug.

7. Recently having taken part in another research study that could interfere with the results of this one.

Healthy Control Exclusion Criteria:

1. Any physical ill health which would render the use of Metyrapone inappropriate, including untreated hypothyroidism, disorders of steroid production, current, severe cardiac failure, current, severe or frequent angina, current renal failure, or myocardial infarction within the last year. NOTE: healthy controls are NOT treated with Metyrapone.

2. Pregnancy, determined by history and, if indicated, urine pregnancy test.

3. Mothers who are breastfeeding.

4. Use of any medication that would interfere, in a pharmacodynamic or pharmacokinetic manner, with Metyrapone.

5. Dependence on alcohol or other drug in the past 12 months, and/or current harmful use of alcohol or other drug.

6. Presence of any metal implants or foreign bodies such as from a surgical implant, accident or injury [this criteria only applies to those undergoing the fMRI scans - this is all 30 healthy subjects recruited in the North West (NW)and 15 of the 25 recruited in the North East (NE)].

7. Recently having taken part in another research study that could interfere with the results of this one.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Depression
• Depressive Disorder

Intervention

Drug:
• Metyrapone
500 milligrams to be taken twice a day orally
• placebo
a matched placebo will be administered to patients to take twice a day for 3 weeks

Locations

Country	Name	City	State
United Kingdom	Bradford District Care Trust	Bradford
United Kingdom	Leeds Community Mental Health Team	Leeds
United Kingdom	Affective Disorders Service	Manchester
United Kingdom	Manchester Community Mental Health Team	Manchester
United Kingdom	Manchester Magnetic Resonance Centre	Manchester
United Kingdom	Newcastle Community Mental Health Team	Newcastle Upon Tyne	Tyne and Wear
United Kingdom	Newcastle Magnetic Resonance Centre	Newcastle Upon Tyne	Tyne and Wear
United Kingdom	North Tyneside Community Mental Health Team	Newcastle Upon Tyne	Tyne and Wear
United Kingdom	Northumberland, Tyne and Wear NHS Foundation Trust	Newcastle upon Tyne
United Kingdom	Regional Affective Disorders Service	Newcastle Upon Tyne	Tyne and Wear
United Kingdom	Stockton Affective Disorders Service	Newcastle upon Tyne	Teesside

Sponsors (2)

Lead Sponsor	Collaborator
Jane Barnes	National Institute for Health Research, United Kingdom

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary outcome will be the change in Montgomery-Asberg Depression Rating Scale (MADRS) from week 0 to +5 weeks.	The primary outcome will be the change in Montgomery-Asberg Depression Rating Scale (MADRS) from week 0 to +5 weeks.	5 weeks	No
Secondary	Secondary outcomes related to mood will be the Montgomery-Asberg Depression Rating Scale (MADRS) measured at time +3, +5, +8, +16 and + 24 weeks relative to baseline.	Secondary outcomes related to mood will be the Montgomery-Asberg Depression Rating Scale (MADRS) measured at time randomisation, +3, +5, +8, +16 and + 24 weeks relative to baseline.	up to 6 months	No
Secondary	Clinical Anxiety Scale (CAS)	Mood as measured by YMRS and BDI at time 0, +3, +5, +8, +16, +24 weeks; Anxiety as measured by the CAS and STAI at time 0, +3, +5, +8, +16, +24 weeks; Quality of life, assessed using the EQ-5D at weeks 0, +3, +5, +8, +16, +24; Tolerability assessed using the TSES and self-report at weeks 0, +3, +5, +8 (additional self-report at weeks +1, +2 and +4); Suicide risk assessed at weeks 0, +1, +3, +5, +8, +16, +24; Hypothalamic-Pituitary-Adrenal (HPA) axis function assessed by salivary cortisol awakening response (CAR) and sample at 11 pm at weeks 0, +3 and +5; Safety assessments including blood pressure, urea and electrolytes and plasma cortisol levels at weeks -2, +1 and +5	up to 6 months	No
Secondary	Quality of life will be assessed using the self-completed EuroQol EQ-5D instrument (http://www.euroqol.org/). The EQ-5D will be completed at 0, +3, +5, +8, +16 and + 24, weeks.	Quality of life will be assessed using the self-completed EuroQol EQ-5D instrument (http://www.euroqol.org/). The EQ-5D will be completed at 0, +3, +5, +8, +16 and + 24, weeks.	up to 6 months	No

External Links

•   Link